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1 Introduction 
 
The advent of the post-genomic era and the development of new high-
throughput analytical technologies led to firmly establish that several 
molecular and environmental components, like nutritional molecules, 
environmental pollutants, chemical compounds with biochemical activity, can 
have a wide spectrum of biological activities, acting on different products of 
the genome. 
This consideration has important implications in several fields ranging 
from molecular biology to nutrition and pharmaceutical chemistry; for 
example leading to rediscover a growing number of pharmacological 
molecules for being active also towards new targets resulting in new 
therapeutic effects or sometimes in previously unrecognized side effects123. 
Consequently, the approach for understanding the mechanisms that 
regulate biological processes was gradually modified for answering to the 
"omic" need of considering all the components expressed and modulated by 
a stimulating factor in different diseases or biological conditions. 
As a consequence over the past ten years the development of 
disciplines such as pharmacogenomic was speeded up with the main 
objective of evaluating the correlation between gene expression and drug 
response in patients by associating different gene profiles with a drug's 
efficacy or toxicity. 
The development of the “omics” disciplines grew in parallel with the 
development of the “omic” analytical technologies and it is now possible to 
completely capture the transcriptome and partially the proteome of a cell 
upon different treatments456. 
The great power of the methods for quantitatively and qualitatively 
measure the mRNA and the proteins produced under specific biological 
conditions is limited by both the intrinsic technical properties of the 
respective technologies and by the low correlation between the types and 
the levels of mRNA dynamically expressed by a genome with respect to the 
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correspondent observed proteins. 
This results in a general difficulty in reconstructing the integrated map 
of the molecular components the expression of which is induced at the 
mRNA level and that are further translated in functional proteins789.  
The high dimensionality of the produced datasets adds another level of 
complexity due to the high number of hypothetical target networks 
modulated by a treatment that can lead to the observed phenotype, resulting 
in the impossibility of testing all of them with experimental approaches10.. 
It is possible to reduce the dimensionality of the data produced by 
omic technologies by screening of biological expression networks with multi-
target docking studies11 or predicting protein-protein12and protein-ligand13 
interactions by means of structure similarities. 
However, also in this case the applicability of methods based on 
computational screening is limited by the number of crystallographic 
structures deposited in PDB database (to date: 1699 structures of human 
proteins) compared to the number of human protein coding genes (21823 
source Ensemble rel62).The disproportion between the known structures 
and the number of genomic products results in the impossibility of covering 
all the proteins functions and shapes encoded by the genome. 
Moreover it is necessary to further consider that 95% of the human 
genes are subjected to alternative splicing so that a gene can express 
different mRNA isoforms as a consequence of specific cellular signals. 
The transcribed isoforms may have low sequence similarities 
between them and might not give raise to proteins because of low stability of 
their mRNA or because targeted by the NMD pathway. 
Finally, even if correctly translated they might produce proteins with 
different ability of interacting with their biological counterparts or ligands14 15. 
A correct assessment of the real capability of the expressed isoforms 
to encode for functional proteins would improve the sensitivity of the 
predictions produced by computational screenings of molecular targets. 
Unfortunately this task cannot be unambiguously answered by 
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experimental approaches. While the presence of a functional protein in the 
cell can be demonstrated, it is impossible to assess that a given peptide 
sequence is not present or functional at any given time or in any 
compartment of a cell or an organism. 
In this case the question is whether computational strategies, relying 
on structural and functional predictions, can help to infer the functional roles 
of the products of transcription.  
If properly used, these strategies could play a critical role in 
investigating protein molecular function and interactions. 
Moreover the combination of the assessment of the functional role of 
the expressed products of transcription with biological informations about the 
structure and dynamics of the underlying pathways and networks could also 
permit to better comprehend the molecular mechanisms that regulate 
biological processes modulated by an environmental or pharmacological 
stimulus. 
Problems associated with the experimental and computational tools 
to be combined are reviewed in the following paragraph. 
 
1.2 Dynamic nature of the human genome 
 
The human genome is a complex structure organized in 
transcriptional units clustered in specific regions of the chromosomes 
(genes) separated by large intergenic non coding regions16.  
Even if the entire nucleotidic sequence of the draft of our genome is 
known, the functional organization of its transcriptional units is not yet firmly 
established. 
This is mainly due to the dynamic and complex nature of the biological 
mechanisms that regulate gene expression and to the way in which genes 
and transcripts are identified on the genome 
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1.2.1 Gene definition methods for predicting the exon-intron structure 
of genes 
 
The complexity of the genomic regulatory mechanism makes it 
impossible to annotate the complete set of transcripts that can be expressed 
only by means of experimental data. 
Current strategies for functional annotation of the genome combine 
the biological information deriving from cDNA expressed sequence tags 
(ESTs) or known protein sequences with computational strategies that 
identify specific nucleic acid sequence motifs that are recognized by the 
cellular machinery responsible for transcribing, processing and translating 
messenger RNA molecules. 
The minimal set of signals that describe the structure of a coding 
sequence (CDS) includes the start and stop codons and the donor and the 
acceptor splice sites for each intron. 
Generally these signals are modeled as position specific scoring 
matrices (PWM) derived from the alignment of functionally related 
sequences attesting the probability of observing a nucleotide in a specific 
position of the signal motif. 
Moving a window of the same size of the signal and associating the 
corresponding probability scores, it is possible to predict the portions of the 
genomic sequence that can originate exons and introns. 
 
1.2.2 Alternative splicing 
 
The determination of the functional organization of a gene is given by 
the way in which the exons are assembled within the genomic portion to 
give, once translated, alternative transcripts. 
The determination of the total number of alternative transcripts that 
the alternative splicing machinery could produce is obtained by mean of 
computational predictions based on hidden markov model (HMM) or support 
vector machines (SVM). 
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Both approaches utilize different features such as splicing signals 
located within the predicted exons and introns1718, phylogenetic 
informations19 or include expression data from exon arrays, RNAseq or 
SAGE expression data20 
 
1.2.3 Genomic databases 
 
The effort to centralize the information derived from the annotated 
sequences and associated annotations produced by the whole genome 
sequencing projects led to the creation of genome browsers. 
The best examples are the three fully established whole-genome 
browsers: the NCBI map viewer, the UCSC genome browser and the 
ENSEMBL browser at Sanger Institute. 
Each of these present by default a set of contributed gene-finding 
predictions from different programs and for each new released assemblies. 
In addition, each site develops its own gene set based on mRNA 
evidence obtained from cDNA and EST sequences supplemented by 
computational predictions. 
A fairly conservative database is ENSEMBL in which only genes 
supported by experimental evidence of at least one isoform via sequence 
homologyare included. 
Apart from these, there exist several genome-browser (ASDb, 
HDBAS, ASPIC) dedicated to collect information from algorithms specifically 
trained on alternative splicing genes.  
Independently from the considered database, many of the annotated 
transcripts are originated by computational pipelines therefore with a degree 
of uncertainty in their determination due to the accuracy limits ofthe used 
prediction algorithms. 
Periodically, with the improvement of splicing prediction algorithms or 
after the release of new versions of the genome, the functional organization 
of entire genes radically changes leading to the disappearing or to the 
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rearrangement of the genomic sequence of their isoforms. 
 
1.2.4 Factors regulating the expression of the coding RNA 
 
Expression of transcription products is regulated at the transcriptional 
and post transcriptional level.  
The transcriptional regulationis realized by transcription factors (TFs), 
such as the TBP-associated factors, or TAF proteins that dynamically act on 
a wide variety of cis-acting regulatory elements21 22 23 24 
Post-transcriptional regulation alters the levels of mRNA expressed 
by the transcriptional regulatory mechanisms and is carried out by several 
systems.  
In first instance, specific regulatory small RNAs can modulate gene 
expression by interacting with target mRNAs favoring their degradation or 
modulating their translation. 
Second, the stability25 of the tridimensional structure of the mRNA 
itself influences the decay rate of expressed transcripts, reducing the affinity 
of unstable mRNAs for proteins deputed to regulate the translation of RNA, 
and post-transcriptional modifications, such as RNA splicing, and editing26 27 
Finally, enzymatic control mechanisms limit the possibility to encode 
for non functional proteins binding to functional motifs in the untranscribed 
regulatory region or monitoring the presence of premature stop codons in 
the coding region, resulting in the consequent degradation of faulty mRNA 
by biological pathways such as the non sense mediated decay pathway. 
These mechanisms are not able to remove all the non functional 
mRNAs and, in several cases, a reduced amount of transcript is translated in 
a non functional protein28 with important implications in the development of 
diseases. 
Several computational methods have been developed to infer mRNA 
stability or its propensity to be targeted by non sense mediated decay and 
recent estimates report that the proportion of potential non sense 
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alternatively spliced transcripts in human genome is roughly 10%29 
Therefore a considerable fraction of isoforms (90%) remains that is 
reasonably not directly targeted by degradation pathways but still modulated 
in its dynamic expression. 
Expression profiling experiments usually take a snapshot of the 
mRNA levels in the cell and do not capture the dynamics of mRNA synthesis 
and breakdown. 
This lack of information on the dynamic component of the regulation 
of mRNA levels limits biological investigations in general and proper 
modeling of transcriptional networks in particular. 
 
1.3 Computational approaches for building omic network and 
screening of molecular target 
 
The biology of an organism (cell, animal, plant) results from the joint 
operation of a large network of biochemical reactions, catalyzed by the 
collaborative action of enzymes encoded in the genome of that organism. 
These reactions form routes that can be grouped in pathways 
surveying different biological functions. 
The effect of biological, chemical or pharmacological compounds is 
carried out through the capability to indirectly or directly modulate proteins 
belonging to biological pathways  
It is therefore possible to extrapolate the phenotypic effect of a 
treatment from the genotypic expression by evaluating the number of 
biological pathways modulated in an omic set of expression data30. 
Even if several databases and tools31 have been developed to assist 
biologists in the extraction and building of the modulated interaction 
networks underlying biological pathways (some of them were utilized in the 
paper III and IV), the power of network reconstruction approach is limited by 
the consideration that the number of experimentally determined interactions 
stored in public databases is an approximations of the real number of 
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interactions taking place among the products of the genome. 
This results in the reconstruction of incomplete networks with large 
groups of not connected proteins/genes making it hard to reconduct the 
modulated genotype to the observed phenotype.  
To enrich the network built by data mining of experimental 
interactions annotated in biological databases, it is possible to use 
computational approaches for predicting new likely interactions not yet 
characterized at the experimental level. 
Some approaches detect interacting features or domains 
evolutionarily conserved in pairs of proteins with unknown interactions32. 
Others simulate the protein-protein33 or the protein-ligand34 binding 
(docking) by mean of estimates of the differential free energy between the 
bound and unbound conformation for each possible complex, considering 
favorable the complexes with negative differences of their free energy.  
The key requisite, which is also the limit of the application of docking 
analyses for multi target screening studies, is the availability of protein 
structures to be utilized in docking simulations. 
As of August 2011 the PDB database contains approximately 1700 
human structures and only 14 human proteins have structures for at least 
two of their alternatively spliced forms35.  
The reduced number of PDB structures with respect to the number of 
genes or proteins that can be a potential target in a network originated from 
expression profile experiments is still inadequate to explore the search 
space of all the possible ligand protein interactions. 
 
1.4 Methods for protein structure and function prediction 
 
The functionality of a protein is strictly related to its structure. 
With the help of modern computational methods it is possible to 
predict the structure of a protein and to also evaluate the presence of 
features related to specific biological functions. 
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The applicability of structural and function prediction methods is 
limited in part by the lack of tools that deal with the problem atthe genome 
scale and by the difficulty to evaluate the efficacyof the obtained predictions 
in discriminating between functional and non functional isoforms within a 
gene. 
 
1.4.1 Protein structure prediction 
 
Basically, structural prediction methods are divided in ab initio 
methods that build models on the basis of physicochemical rules and search 
for the most thermodynamically stable structure under physiological 
conditions,and methods that build structures (called targets) on the basis of 
their homology with evolutionary related proteins thestructure of whichhas 
been experimentally determined (named template). 
The application of both approaches to annotate the genome has 
several bottlenecks. 
The first approach is particularly expensive in terms of computational 
resources making extremely difficult to apply these methods to model entire 
genomes and is as yet feasible only for very small proteins.  
The homology modeling methods are less expensive in terms of 
computational resources and potentially easy to apply atthe genomic scale 
but their application is limited primarily by the availability of deposited 
crystallographic structures (templates). 
Moreover, it is necessary to consider that the reliability of the 
homology models is strongly influenced by the accuracy in the alignment 
between target and template sequences in order to correctly detect 
structurally and evolutionary related residue pairs. 
Often, the existing automated pipelines for building models allow user 
provided sequence alignments to be used in order to give the possibility to 
the user to manually check and improve the overall quality of the alignment 
and/or the selection or removal of templates. 
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This manual approach is useful when a limited number of models are 
required but unfeasible when the number of models to be obtained is at the 
genomic scale. 
 
1.4.2 Functional annotation of proteins 
 
The rapidly increasing amount of proteins sequence data make it 
impossible to functionally annotate all the produced sequences only on the 
basis of experimental evidences, therefore most functional annotations are 
produced by computational methods that recognize features at the primary 
structure level. 
Functional annotations tools can be divided in tools that detect 
cellular localization signals or post-translational modifications and tools that 
predict biological functions according to the alignment of protein sequences 
with sequence profiles of modular protein domains36 or short functional 
motifs3738. 
Profiles are elaborated by classifying protein sequences accordingto 
thermodynamic39, structural40, evolutionary41 and functional factors42.  
The tools that evaluate the presence of functional domains assign the 
presence of domains on the basis of the local alignment of the aminoacid 
sequence with profiles of sequences with known domains. 
Splicing isoforms often differ for limited portion of their sequence due 
to the insertion or removal of limited number of exons, therefore commonly 
used tools can assign functional domains even if they are represented by 
small portions of sequences, i.e. incomplete. This aspect limits the sensitivity 
of the functional annotation pipelines posing the question of which is the 
minimum portion of a functional domain necessary for considering the 
domain structured and functional. 
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1.5 Computational analysis of ENCODE data 
 
In 2007 the pilot phase of the encode project,aimed at identify all the 
functional elements in 44 selected regions that make up 1% of the human 
genome,was completed. 
The obtained results43 highlighted several important features of the 
human genome, remarking the central role of alternative splicing in 
regulating gene expression and detailing a reference set of manually 
annotated splice variants by the GENCODE consortium44. 
The in depth computational analysis of the GENCODE transcripts 
was the first attempt to evaluate the coding potential of alternative splicing 
isoforms and suggested that a large number of the analyzed splice variants 
(around 50%) are likely to encode for proteins with potentially deleterious 
changes in their protein structure and function.  
In the following years other studies addressed the same question 
with controversial conclusions. 
Some evidences reported splicing events that produce variants 
showing novel and sometimesunexpected structural and functional 
properties45compared to their native counterparts. Others reported that 
splicing events not conserved across different species are more likely to 
produce protein with big rearrangement of their sequences resulting in 
unstable conformations46. 
These findings raised several interesting questions, but also a few 
practical issues.First of all, the careful manual analysis performed on not 
more than the 1% of the genome needs to be scaled up to the whole 
genome and therefore automated. Secondly, there’s a global need of user-
friendly computational tools that can assist biologists to setup and analyze 
their omic experiments. 
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1.6 Aim and contribution of the study 
 
The purpose of the study described here is to contribute to the field of 
functional genomics by developing, testing and applying computational 
methods to the problem of the evaluation of the effects of environmental and 
pharmacological molecules on genome expression. 
Original results are described in four independent papers that 
address the general problem of identifying potential pharmaceutical targets 
and study their susceptibility to external interfering agents. 
The first two papers are devoted to the investigation of the coding 
potential of alternative splicing products in the human genome. As previously 
mentioned, the assessment of the real capability of the expressed isoforms 
to code for functional proteins is of fundamental importance because would 
permit to gain insights in the biological meaning of the expression data 
produced by the omic technologies and to improve the sensitivity of the 
predictions produced by computational screenings of molecular targets. 
In the first paper, taking advantage of omic databases, we assessed 
the power of computational strategies to infer the functional roles of the 
products of transcription. 
The second paper describes the implementation and benchmark of 
the MAISTAS structural prediction server which is able to analyze the 
structural plausibility of the isoforms produced by alternative splicingat a 
genomic scale. 
Papers three and four are devoted to the application of computational 
techniques to investigate the molecular targets and the effects on their 
expression of molecules known to interfere with the physiological functions 
of a cell.  
In particular these techniques were applied on a class of compounds 
(tocotrienols) constituents of the Vitamin E.  
Paper three explores the possibility that specific classes of 
tocotrienols bind specific subtypes of the nuclear estrogen receptor taking 
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advantage of docking studies followed by experimental validation.  
Paper four investigates the molecular mechanism leading to the 
arrest of cell cycle in breast cancer cells after treatment with specific 
tocotrienols by analyzing microarray experiments and the implied pathways 
and networks. 
This second part of the work was carried out at I.N.R.A.N. in the 
group of Dr Fabio Virgili and the biological experiments analyzed and 
mentioned in the present work were produced by Dr.ssa Raffaella Comitato 
and Dr. Roberto Ambra. 
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2 Results 
 
This chapter shortly outlines the main results obtained during this 
work and detailed in the research papers.Results are divided in two sections. 
The first section is devoted to the general problem of the evaluation 
of the coding potential of alternative splicing. The second section reports the 
application of computational methods to evaluate the capability of bioactive 
molecules constitutive components of vitamin E, to modulate the human 
genome expression. 
Findings in each area are presented in the context of related 
research. 
 
2.1 Capability of computational methods to infer the functional role of 
the products of transcription  
 
Alternative splicing is the preferred mechanism used to quantitatively 
control the gene expression and functionally diversify proteins produced by 
the same gene. 
Estimates of the amount of alternative splicing in human have risen 
dramatically over recent years, especially since the advent of high 
throughput transcriptomic sequencing474849 technologies, reaching up the 
95% of the multi-exons genes50. 
Despite the increasing of the overall number of sequences annotated 
in genomic databases is still unclear the exact functional role of protein 
isoforms produced by splicing. 
Modern proteomic analysis techniques allow the identification, 
characterization and quantization of up to several thousands of proteins in a 
single experiment51. 
Therefore it is theorically possible to compare transcriptomic and 
proteomic expression profiles in order to assess the correlation between 
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mRNA and protein levels in the system of interest. 
Although the detection of a proteomic peptide identifying an isoform 
does not conclusively ensures that it is functional, it does imply that the 
corresponding transcript is translated into a protein likely to fold and be 
produced at sufficient levels to be detected. 
Small scale applications of this concept produced interesting results 
on limited datasets of 16 human genes52 and 130 fruit fly genes53. 
Unfortunately, a large scale survey is still difficult to realize because 
the high throughput proteomic techniques, even if approaching the genomic 
scale, are still not able to detect and quantify all the peptides produced by 
protease digest and this hinders the analysis. 
Given these premises, computational methods are the only way for 
obtaining a probabilistic estimate of the likelihood that a protein is functional. 
In paper I we assessed how these strategies can help to correctly 
recognize functional transcription products likely to be translated. 
Such estimate has been performed in two steps. First we evaluated 
how well methods for the prediction of the structural and functional 
plausibility are able to identify alternative splicing isoforms unambiguously 
identified by proteomic expression data. 
Next we applied the same methods to isoforms of the same genes 
that are not detected in any publicly available proteomic experiment 
database, even if potentially detectable. 
To build the datasets the coding portion of the alternatively spliced 
genes stored in Ensemble (ver57) was characterized defining the specific 
and the aspecific portions of the exonic sequences of each isoform 
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Proteomic peptides were mapped on the specific exons included in 
transcript sequences. Isoforms unambiguously identified by peptides 
(mappingtotheir specific exons) were included in the positive dataset only if it 
was possible to select another isoform of the same genenot identified by 
proteomic peptides but potentially identifiable (i.e. with specific parts in its 
sequence potentially detectable by mass spectrometry).The detailed pipeline 
is described in paper I. 
The analysis was carried outby evaluating, for each isoform, its 
structural plausibility, based on structural models built by homology, the 
Figure 1: Characterization of the coding portion of human genome (Ensemble57) In the 
pie chart the percentages of different types of exons in the coding portion of alternatively 
spliced genes are represented. The specific parts of exonic sequences in isoforms 
belonging to the same gene are depicted in grey. 
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presence of complete domains, based on the Pfam domain definition, the 
presence of functional sites such as catalytic sites or ligand binding sites, 
based on SwissProt annotated features54.  
The application of the previously mentioned strategies necessarily 
implied the establishment of generally valid criteria to assess the likelihood 
that an isoform is structurally and functionally plausible. 
For functional features, such as catalytic sites and ligand binding 
sites, the criterion was easily established and consisted in verifying the 
removal of functional sites experimentally determined and annotated in 
SwissProt database. 
The assessment of functional plausibility in terms of the presence of 
functional domains was more complex. 
It is known that alternative Splicing can remove whole protein 
domains, but tends not to occur within domains55. It is therefore reasonable 
to assume that isoforms with truncated domains are the result of an incorrect 
event of splicing more than of a regulated event or that they have a 
completely different function from the cognate isoform with a complete 
domain. 
The first question is which is the minimum portion of a functional 
domain necessary for considering the domain itself as structured and 
functional.  
To answer to this question, all the human protein sequences for 
which the structure is known were analyzed; assessing to which extent their 
sequences cover profiles representing known classes of functional domains. 
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Structural predictions were evaluated by estimating several 
parameters: the quality of the packing of the core model structure, the extent 
of the hydrophobic surface exposed to solvent and the presence of insertion 
and deletions that could not be accommodated without larger modification 
with respect to the structural template. 
The assessment of isoforms plausibility according to the previously 
described criteria, reveals that the isoforms whose existence is confirmed by 
proteomic are strongly enriched in “positive” parameters (i.e. parameters that 
are similar to those observed for experimentally confirmed proteins) than the 
isoforms not confirmed by proteomics data. 
90% of the positive modeled isoforms appear to be structurally 
plausible or with integer functional domains, while only 40% of the isoforms 
Figure2: Coverage of PFAM domains in PDB structures: The plot shows the percentage 
of coverage of PFAM domain sequence profiles in 3859 PDB structures of human 
proteins with less of 30% of sequence homology. The 90% of domains (in green box) 
cover the corresponding PFAM profile for more than 70%.Therefore this threshold has 
been chosen for considering a domainas structured and functional 
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in the datasets not confirmed by proteomic have plausible structural and 
functional parameters. 
The combination of structural and functional parameters in each 
isoform has been used for assessing the sensitivity of the computational 
strategies in the identification of isoforms produced bya regulated alternative 
splicing event (summary of the statistical analysis is reported in Table1). 
 
 
 
 
 
 
 
 
 
 
 
 
The combination of the three criteria described above provides the 
most accurate prediction being able to identifythe 80% of these isoforms 
even if this combination is applicable only in a limited fraction of cases (5%). 
The most limiting criterion is the detection of the presence of 
functional sites due to the limited amount of cases for which this feature is 
annotated. 
Considering only if an isoform has not interrupted functional domains 
or has a plausible structure results in the more useful criterion of evaluation, 
applicable in most cases with high accuracy. 
The absence of a well defined negative set does not allow the 
estimate of the exact number of false positives i.e. the number of isoforms 
not translated in proteins but predicted as plausible; however the estimates 
Table 1:Assessment of the sensitivity of structural and functional parameters 
25   
` 
obtained on positive isoforms highlight the power of computational methods 
for inferring the functionality of transcription products.  
 
2.2 Large scale automatic structural evaluation of genome products 
 
The work described in paper I highlights the importance of the 
structural predictions for inferring isoform functionality. 
However, there are still few automatic publicly available instruments 
that allow structural predictions to be obtained at the genomic scale and 
most of them only collect models already existing56 or provide information 
about the putative effect of alternative splicing provided that at least one of 
the isoforms has an experimentally solved structure57. 
During this PhD project a publicly available server named MAISTAS 
(described in Paper II) has been implemented and benchmarked. MAISTAS 
collects and builds, whenever possible, comparative homology models for all 
the putative spliced isoforms of the genes in genomes stored in the 
Ensemble database, providing an estimate of the likelihood that the isoforms 
correspond to potentially stable and structurally plausible proteins in the 
absence of major conformational rearrangements. 
The assessment of the structural plausibility of the obtained models is 
performed comparing their structural properties with those observed in 
known protein structures and in the closest homologs of known structure  
More specifically, models are evaluated by assessing the putative 
effect of deletions and insertions of parts of their sequence compared with 
the sequence of the closest template, the packing of the core of themodeled 
structures andthe extent of their exposed hydrophobic surface. 
The server was benchmarked on the entire dataset of human 
alternatively spliced isoform whose existence at the protein level could be 
unambiguously verified by mass spectrometry according to PeptideAtlas 
database.  
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In benchmark tests, MAISTAS was able to produce and analyze 
models in 30% of the cases. In the 70% of the to be modeled sequences the 
model could not be built because there is no protein of known structure 
satisfying the parameterschosen for considering it as a good template.  
Out of the modeled isoforms, the 80% was assessed as structurally 
plausible.In the majority of the remaining cases, the obtained model showed 
a large hydrophobic surface exposed to the solvent. 
In these cases, the protein might indeed represent an incomplete and 
therefore not plausible structure, but it could also be a subunit of a larger 
complex. 
 
2.3 Computational methods for the identification of molecular targets: 
Vitamin E case study 
 
Vitamin E is a generic term used to refer to a family of fat-soluble 
compounds composed by α, β, γ, δ-tocopherols and corresponding four 
tocotrienols58.  
Several studies report that α, γ, δ tocotrienols have a wide spectrum 
of specific functions and activities (ranging from antioxidant activity to the 
protection against the stroke and diabetes typeII) distinct from those 
attributed to tocopherols59 60 
Moreover in recent years there is evidenceof a role associated with a 
possible “anti-cancer” activity exhibited by tocotrienols achieved by 
modulating the cell cycle and inducing apoptosis in prostate and breast 
cancer cell lines6162 . 
Despite the growing interest about the potential applications of these 
alimentary compounds as dietary supplement in order to coadjuvate the 
pharmacological therapies for cancer treatment63, the mechanism of action 
underlying their activities and their molecular target(s) are still poorly 
understood. 
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The broad spectrum of tocotrienols activities suggests that the 
molecular target through which their activities are carried out is in a central 
position in different biological pathways or alternatively that tocotrienols 
could be able to bind more biological receptors related to different biological 
functions. 
Tocotrienols, therefore, represent a suitable case study in which the 
computational methods can be used to drive and interpretate experimental 
results in order to elucidate the mechanism of action of these molecules.   
The analysis of expression data from cDNA array experiments 
previously performed at I.N.R.A.N. on cultured human breast cancer cells64, 
in sub-cutaneously implanted athymic mices65 and on stripped culture 
mediums (characterized by total removal of lipidcomponents of serum, 
including estrogens), indicated the possibility that the biological activities of 
tocotrienols could result from interaction with the estrogen receptor related 
signaling. 
In order to confirm or discard this novel hypothesis docking studies to 
estimate the theorical propensity of α, γ, δ tocotrienols to bind the two 
isotypes of the estrogens receptor (ERα, ERβ) in their active and inactive 
conformation were performed. 
The results (detailed in paper III) suggest thattocotrienolscan 
preferentially bind the ERβ in its active conformation with a binding mode 
similar tothat of estradiol (the estrogenic hormone, which is the natural ligand 
of this receptor).  
With the help of computational techniques it was also possible to 
estimate the levels of activity (expressed in terms of the theoric binding 
energy of the docked compound within the receptor) shared by different 
tocotrienols, highlighting the decrease of their activity inversely related to the 
number of methyl groups in their phenolic ring. 
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The quantitative differences in tocotrienols activity and the preference 
for a specific receptorial isotype were subsequently confirmed by in vitro 
binding-displacement test analyses (Figure 3). 
Displacement tests cannot provide any information about the ability of 
these compounds to place the receptor in an active or an inactive 
conformation. Therefore experiments of indirect immunofluorescence, 
monitoring the cellular localization of estrogen receptor upon tocotrienols 
treatment in breast cancer cells (MDA) expressing only the isotype beta at 
protein level, were performed. 
Also in this case the results obtained by docking were confirmed 
revealing that, upon tocotrienol binding, ERβ is able to translocate into the 
nucleus of the cell to exert its transcription factor activity similarly to the 
receptor activated by estradiol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3:Binding displacement test and docking results: Displacement binding analyses of 
tested compounds (estradiol, α, γ and δ tocotrienols) versus ERα(A,B,C,D) and 
ERβ(A’,B’,C’,D’). According to the obtained results only γ and δ tocotrienol were able to 
bind ERβ. On the left (E) the superposition between crystallographic structures of ERβ 
(PDB: 1X7J) bound to estradiol (structure in cyan and ligand in orange) and the best 
dockingcomplex in δ tocotrienol simulationsare shown. 
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The results of paper III undoubtedly highlighted the potentialities of 
docking methods for screening molecular targets but also pointed out one 
limit of the technique: the difficulty to compare and to rank different binding 
energies in different protein-ligand complexes. 
The problem was addressed in the tocotrienol case study using a 
qualitative evaluation of the solutions produced in each docking. We 
compared the binding energy of the most favored solutions (by mean of 
clustering) with those of the reconstructed natural ligand-receptors 
complexes. 
This implies that there is still room for improvement and more effort 
should be put indeveloping and testing “normalization” procedures of the 
binding scores across different resultsobtainedby docking experiments. 
 
2.4 Pathway and network analyses: Involvement of the estrogen 
receptor beta signal transduction in tocotrienol activity  
 
The application of pathway and network analyses to omic expression 
data can help reconstructing the regulatory interplay related tothe biological 
activity of a target. 
The potential of these methods was explored by studying the 
mechanism leading to the arrest of cell cycle and apoptosis in breast cancer 
cells after tocotrienols treatment. 
The results obtained and described in paper III highlighted the role of 
the ERβ as a potential biological target of tocotrienols. 
Several studies on cell and animal models report that this receptor is 
the gateway of several biological pathways and its biological action is the 
result of an intricate regulatory interplay not completely understood and 
involving ERα. 
The two receptorial isotypes are expressed by different genes and 
perform partially overlapping biological functions66. 
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In several tissues they are co-expressed and usually ERβ,when 
activated, exhibits an inhibitory action on ERα-mediated gene expression67.  
Besides this “antagonist” relationship between the two receptors, it 
has also been recently observed that there is a “synergistic” relationship in 
some biological districts directed to positively modulate the same biological 
functions. 
An example of this is the neuroendocrine tissue in whichERβleads to 
an increase of the amount of produced oxytocin peptide, while ERα 
increases expression of its receptor68. 
It follows that the biological response after the activation of ERβ 
could vary depending on the biological district or condition considered and 
on the co-expression the two receptors. 
Tocharacterize the regulatory gene expression profile induced by 
different tocotrienols, microarray experiments were performed on breast 
cancer cells (MCF7) expressing constitutively both ERα and ERβ. 
Lists of differentially modulated genes after γ and α tocotrienol 
treatment versus control were produced and subsequently submitted to 
network and overrepresented pathway analysis, providing insightson the 
tocotrienols mechanism of action in MCF7 cells.  
Microarrays analysis suggests that, in breast cancer cells, the 
mechanism of action ofERβ upon tocotrienol treatment is mainly explicated 
via an antagonistic relationship with Erα-mediated gene expression. 
This is highlighted by the observed down regulation of Era 
expression together with the up regulation of genes encoding for repressors 
of transcription factors (NRIP1, THR, HEXIM1, MECP2). 
According to the pathway and network analysis (detailed in paper IV) 
these genes belong to a common sub network of interaction involving ERβ. 
We also found that, the p53 tumor suppressor (downstream ofErα) 
gene expression is up regulated. 
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Evidences report that ERα is able to repress the expression of this 
cellular death inducing gene and that the lowering of the control on 
p53expression could increase the signal of cell death. 
The decrease in ERα expression and the activation with consequent 
nuclear translocation of ERβ were also confirmed by immunofluorescence 
experiments. 
Pathway analysis suggested the specific capability of γ tocotrienol to 
modulate pro-apoptotic genes (CASP10, BID, AIFM1, APAF1). Several 
mitochondrial genes appeared to be negatively modulated after γ tocotrienol 
treatment (COX4L1, BCL2A1) together with the SERCA3 ATPase 
responsible for the reabsorption of cytosolic calcium inside the 
endoplasmatic reticulum. 
Interestingly, the increase of cytosolic calcium is one the major 
mitochondrial pro-apoptotic signals69. 
All these evidences suggest that the molecular mechanism 
underlying γ tocotrienol inducedapoptosis in MCF-7 cells is, at least in part, 
mitochondriadriven. 
With the help of omic network analyses it was therefore possible to 
partially interpretate the gene expression profiles produced by microarrays 
and assess the presence of genes that belong to pathways likely to be 
modulated by tocotrienols treatment.  
It should also be mentioned, though, that the analysis of the 
interaction network between modulated genes resulted in many cases 
difficult to interpretate. 
Many modulated genes have context dependent functions and it is 
not possible to exclude that the change in their expression levels is not 
directly connected to the treatment. 
An example in the presented case study is the observation, after 
treatment with γ tocotrienol, of the up regulation of few genes related to the 
development of mammary carcinoma (detailed in paper IV). 
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Their up regulation could be due an adaptative response to the pro-
apoptotic stimulus or to interactions not yet annotated in public databases or 
be a false positive result of microarrays analysis 
Furthermore we cannot exclude that some of the over expressed 
transcripts exert their biological activity throughone of their alternatively 
spliced isoform. 
We think that a more accurate analysis at the isoform level, now 
possible thanks to the development of next generation sequencing 
techniques, together with the application of computational methods for 
evaluating the plausibility of the expressed isoforms could help to achieve 
more sound results. 
On the other hand the determination of the tridimensional structure of 
single isoforms could also increase the accuracy of computational methods 
for investigating protein-ligand or protein-protein interactions allowing the 
prediction of interactions still not annotated or the identification ofoff-targets 
responsible for activating biological pathways not directly connected to the 
main effect observed after tocotrienol treatment. 
33   
` 
3 Conclusions and outlook 
 
In order to identify hypothetical molecular targets in genome 
expression products, it is fundamental to evaluate the functional role of the 
transcriptional units in which the genome is organized and to consider that 
bioactive molecules can bind to different targets resulting in different 
biological activities or side effects in case of molecules with therapeutic 
activities. 
The computational analysis of data produced by the pilot phase of 
ENCODE project suggested for the first time the great potential of 
computational methods to investigate the properties of the functional 
elements produced by the 1% of the genome raising the question if these 
methods could be used on a genomic scale to elucidate the function of the 
encoded transcripts and the molecular mechanisms underlying the biological 
effects subsequent to their modulation. 
The present work started from this question with the aim of scaling up 
the analysis performed on the 1% of the genome to comprehend the 
functional role of genome products and to highlight the potential and some 
bottlenecks of currently available tools for the prediction of protein structures 
and functions at the genomic scale as well as of tools for analyzing ligand- 
protein and protein-protein interactions in “omic”expression networks. 
The application of structural and functional prediction methods to all 
the genomic products requires the development of tools that permit to model 
and compare with reasonably and widely applicable criteria a large number 
of sequences. 
The development and the benchmark of the first method to analyze 
the structural properties of all the alternative splicing isoforms produced by 
the genome confirms that this is a viable route to start addressing the 
challenges of the post-genomic era. 
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The application of the homology modeling for structural prediction is 
partially limited by the availability of suitable templates. However, it is 
reasonable to assume that this limitation will be overcome by the 
development of high-throughput protein crystallization platforms70 and/or by 
improvement of techniques that combine ab-initio structure prediction 
methods with homology modeling of fragments of the query sequence on the 
basis of local similarities with templates.  
This latter approach is a good compromise between the pure ab initio 
methods that require large computational resources and homology modeling 
methods that are easier to implement but have a limited coverage.  
Some recently developed tools that use such as approach71 won the 
last 3 editions of CASP, thecommunity-wide experiment for testing the state-
of-the-art of protein structure predictions. 
By mean of the characterization of the coding portion of human 
genome, we have shown that the prediction of the structure and function of 
alternatively spliced proteins can be instrumental in identifying cases in 
which transcribed isoforms without experimental evidence of existence as 
proteins have properties significantly different from isoforms of the same 
gene that have beenexperimentally confirmed at the protein level. 
The high percentage of “unusual” isoforms observed in our study 
(around 40%) is quite similar to the percentage of isoforms with drastic 
alterations in their structure and function observed in the computational 
analysis of ENCODE data (around the 55%) and poses the key question of  
which could be their functional role. 
A first hypothesis could be that the different structural and functional 
parameters produce a completely different structure and function with 
respect their spliced counterparts expanding the coding potential of their 
originating gene. Alternatively the change of their structural and functional 
properties could be used to modulate the biological activity of the gene 
products. In these two cases, alternative transcripts would increase the 
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repertoire of protein functions.  
There are few experimental evidences72 73documented in literature 
supporting this hypothesis, however we think that the large number of 
observed isoforms with unusual structural and functional parameters makes 
unlikely that this explanation holds for all of them. 
On the other hand, some of these isoforms could encode for 
functional RNAs74 or exert a regulatory function interacting and perhaps 
inhibiting other proteins75.A fraction of the transcripts could also be originated 
by “non correct” alternative splicing events and one could speculate that the 
cell tolerates these “non correct” variants to some extent because produced 
in low numbers since they could represent de facto evolutive reservoirs on 
which the selection pressure against exon loss or substitution is reduced 
making large evolutionary changes possible.    
It is also possible, and perhaps likely that some of the splicing 
isoforms produced at high levels are the result of “aberrant” events perhaps 
linked to diseases76. 
Obviously the phenomenon that we observed admits too many 
possible explanations and it will not be easy to test all of them (especially 
since each of them can apply to a subset of the cases) and to provide a 
conclusive and general answer. Certainly the integration of new large scale 
experimental data produced by more powerful high throughput technologies 
together with other computational analyses not only limited to the 
assessment of functional and structural properties will help interpreting their 
functional role. 
In this perspective the work described here is to be intended as a first 
step and should be complemented in the near future with the analysis of 
other functional features that can be modified by alternative splicing, such as 
the modification of cellular localization signal, protein disorder, propensity to 
be targeted by decay mechanisms, mRNA stability. 
It is clearly important to continue in this direction because the 
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understanding of the coding potential of eukaryote genomes is certainly 
required for understanding the molecular mechanisms that regulate 
biological processes and their modulation by bioactive molecules. This 
aspect is being actively addressed since it has important implications for 
human health and nutrition as demonstrated by our study of the molecular 
targets of bioactive molecules (tocotrienols) constituents of Vitamin E in 
different breast cancer cellular models and of the effect of the molecules on 
gene expression. In this case, we used docking techniques combined with 
an assessment of overrepresented pathways and on the reconstruction of 
interaction networks from transcriptomic expression profiles. 
The rationale of our choice of tocotrienols is due to the observation 
that, despite the increasing concern about the potential applications of these 
alimentary compounds as dietary supplement to coadjuvate the 
pharmacological therapies for cancer treatment, the mechanism of action 
underlying their activities and their molecular target(s) are still poorly 
understood.  
Interestingly, our computational results highlighted that the products 
of differential gene expression observed in breast cancer cells after 
treatment with specific subtypes of tocotrienols are linked to induction of 
apoptosis.  
The analyses of the involved networks and pathways also indicated 
that several transcription factors, related to induction of apoptosis, modulate 
part of a network of interaction that includes the estrogen receptor beta. 
Docking simulations, confirmed by displacement assays in vitro, 
indicated that Erβ is a molecular target of tocotrienols that act by binding in 
its active site.  
Since immunofluorescence experiments evidenced the capability of 
ERβ to translocate in cellular nucleus after tocotrienol treatment, it is 
conceivable that tocotrienols are able to activate this receptor stimulating its 
transcriptional activity. 
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The application of computational methods for the detection of targets 
of vitamin E underlines the potential but also some of the limitations of the 
available computational methods. For example, the reconstruction of the 
network of interactions and the analysis of modulated pathways explains 
only a fraction of the total number of modulated genes, making it hard to 
reconduct the overall genotype to the observed phenotype.  
It is reasonable to suppose that the more accurate analysis at the 
isoform level, now possible thanks to the development of next generation 
sequencing techniques, together with the application of methods for the 
determination of the tridimensional structure of single isoforms, could 
increase the accuracy of computational methods for investigating protein-
ligand or protein-protein interactions and allow the prediction of as yet 
unknown interactions and/or the identification of off-targets responsible for 
activating biological pathways not directly connected to the main effect 
observed after treatment. 
The ambition of understanding of the complexity of the functional 
content of our genome and of the intricate relationships between the different 
pathways and networks is probably no within easy reach as of today, but 
efforts such as those described here can hopefully be useful to reach this 
important and exciting goal. 
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